As filed with the Securities and Exchange Commission on September 2, 2016
Registration Statement No. 333-
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-3
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ARROWHEAD
PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
46-0408024
|
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification Number)
|
225 South Lake Avenue, Suite 1050
Pasadena, California 91101
(626) 304-3400
(Address,
including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Christopher
Anzalone, Chief Executive Officer
Arrowhead Pharmaceuticals, Inc.
225 South Lake Avenue, Suite 1050
Pasadena, CA 91101
(626)
304-3400
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Ryan
Murr
Gibson, Dunn & Crutcher LLP
555 Mission St., Suite 3000
San Francisco, CA 94105-0921
Telephone: (415) 393-8200
Facsimile: (415) 393-8306
Approximate Date of
Commencement of Proposed Sale to the Public:
From time to time after this Registration Statement becomes effective, as determined by the selling stockholders.
If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the
following box.
¨
If any of the securities being registered on this Form are to
be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box.
x
If this Form is used to register additional securities for an offering pursuant to Rule
462(b) under the Securities Act, please check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same
offering.
¨
If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities Act Registration Statement number of the earlier effective registration statement for the same
offering.
¨
If this Form is a registration statement pursuant to General
Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following
box.
¨
If this Form is a post-effective amendment to a registration statement
filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following
box.
¨
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange
Act.
|
|
|
|
|
|
|
|
|
Large accelerated filer
|
|
¨
|
|
Accelerated filer
|
|
x
|
|
|
|
|
|
|
Non-accelerated filer
|
|
¨
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
|
¨
|
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
|
|
|
Title of Each Class of
Securities to be Registered
|
|
Amount
to be
Registered(1)
|
|
Proposed
Maximum
Offering
Price
per Share(2)
|
|
Proposed
Maximum
Aggregate
Offering Price(2)
|
|
Amount of
Registration Fee
|
|
Common Stock, par value $.001 per share
|
|
7,627,119
|
|
$6.78
|
|
$51,711,866.82
|
|
$5,207.39
|
|
|
|
|
|
(1)
|
Pursuant to Rule 416 of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers such additional securities as may become issuable to prevent dilution resulting
from stock splits, stock dividends and similar events.
|
|
(2)
|
Pursuant to Rule 457(c), calculated on the basis of the average of the high and low prices per share of the registrant’s Common Stock reported on the Nasdaq Global Select Market on August 29, 2016.
|
The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration
Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
The information in this prospectus is not complete and may be changed. We may not sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the
offer or sale is not permitted.
Subject to Completion, dated September 2, 2016
Prospectus
Arrowhead Pharmaceuticals, Inc.
7,627,119 shares of Common Stock
This prospectus covers the sale of an aggregate of
7,627,119 shares of our Common Stock, $0.001 par value per share (the “Shares”), by the selling security holders identified in this prospectus (collectively with any donees, pledgees, transferees or other successors-in-interest selling
shares of Common Stock or interests in shares of Common Stock received after the date of this prospectus from such selling security holders as a gift, pledge, partnership distribution or other transfer, the “selling stockholders”). The
Shares covered by this prospectus were issued to the selling stockholders on August 11, 2016 pursuant to that certain Securities Purchase Agreement, dated August 8, 2016 (the “Securities Purchase Agreement”), by and between the
Company and the selling stockholders.
The Company will not receive any proceeds from the sale by the selling stockholders of the Shares. We are paying the cost of
registering the Shares covered by this prospectus as well as various related expenses. The selling stockholders are responsible for all selling commissions, transfer taxes and other costs related to the offer and sale of their shares.
Sales of the Shares by the selling stockholders may occur at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market
prices or at negotiated prices. The selling stockholders may sell shares to or through underwriters, broker-dealers or agents, who may receive compensation in the form of discounts, concessions or commissions from the selling stockholders, the
purchasers of the Shares, or both. If required, the number of shares to be sold, the public offering price of those shares, the names of any underwriters, broker-dealers or agents and any applicable commission or discount will be included in a
supplement to this prospectus, called a prospectus supplement.
The Company’s Common Stock is traded on The Nasdaq Global Select Market under the symbol
“ARWR.” On September 1, 2016, the closing sale price of our Common Stock on The Nasdaq Global Select Market was $7.06 per share. Our principal executive offices are located at 225 South Lake Avenue, Suite 1050, Pasadena,
California 91101, and our telephone number is (626) 304-3400.
Investing in our securities involves a high degree of risk. You should carefully consider the
Risk Factors
beginning on page 2 before you invest in our securities.
Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is September , 2016
Table of Contents
ABOUT THIS PROSPECTUS
You should read this prospectus, any applicable prospectus supplement and the information incorporated by reference in this prospectus before making an investment in
the securities of Arrowhead Pharmaceuticals, Inc. See “Where You Can Find Additional Information” for more information, page 6. You should rely only on the information contained in or incorporated by reference in this prospectus or a
prospectus supplement. We have not authorized anyone to provide you with different information. This prospectus may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that information contained
in this prospectus, or in any document incorporated by reference, is accurate only as of any date on the front cover of the applicable document. Our business, financial condition, results of operations and prospects may have changed since that date.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus contains certain “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995, and we
intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this prospectus except for historical information may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue” or the
negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other
characterizations of future events or circumstances are forward-looking statements.
The forward-looking statements included herein are based on current
expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results may
differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 1 (Business) and Item 1A (Risk
Factors) of Part I and Item 7 (Management’s Discussion and Analysis of Financial Condition and Results of Operations) of Part II of our most recent Annual Report on Form 10-K, factors described under the section captioned “Risk
Factors” in this prospectus, as may be updated from time to time by our future filings under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and elsewhere in the documents incorporated by reference in this
prospectus. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (the “SEC”). In light of the significant risks and
uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to
place undue reliance on such forward-looking information. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.
ABOUT THE COMPANY
Unless otherwise noted: (1) the term “Arrowhead” refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation, formerly known as Arrowhead
Research Corporation and InterActive Group, Inc., (2) the terms the “Company,” “we,” “us” and “our” refer to the ongoing business operations of Arrowhead and its subsidiaries, whether conducted through
Arrowhead or a subsidiary of Arrowhead, and (3) the term “Common Stock” refers to shares of Arrowhead’s Common Stock and the term “stockholder(s)” refers to the holders of Common Stock or securities exercisable for
Common Stock.
Arrowhead develops novel drugs to treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries
and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (RNAi) is a mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company’s pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus,
ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease and ARC-HIF2 for renal cell carcinoma.
Our executive offices are located at 225 South Lake Avenue, Suite 1050, Pasadena CA 91101 and our telephone number is (626) 304-3400. Additional information
regarding our company, including our audited financial statements and descriptions of our business, is contained in the documents incorporated by reference in this prospectus. See “Where You Can Find More Information” on page 6 and
“Incorporation of Certain Information by Reference” on page 7.
1
RISK FACTORS
Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described in the sections
entitled “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on form 10-Q, as filed with the SEC, which are incorporated herein by reference in their entirety, as well any amendment or updates to
our risk factors reflected in subsequent filings with the SEC, including any applicable prospectus supplement. Our business, financial condition, results of operations or prospects could be materially adversely affected by any of these risks. The
trading price of our securities could decline due to any of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks
and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned elsewhere in this prospectus. For more information, see the
section entitled “Where You Can Find More Information.”
USE OF PROCEEDS
The proceeds from the resale of the Shares under this prospectus are solely for the account of the selling stockholders. We will not receive any proceeds from the sale
of Shares under this prospectus.
2
SELLING STOCKHOLDERS
The Company has included in this prospectus 7,627,119 shares of Common Stock, which were originally issued to the selling stockholders on August 11, 2016 pursuant
to the Securities Purchase Agreement. In connection with the consummation of the transactions contemplated by the Securities Purchase Agreement, we agreed to file a registration statement with the SEC covering the resale of the Shares.
The following table sets forth certain information regarding the selling stockholders and the shares of Common Stock beneficially owned by each of them, which is based
on information that is available to us as of September 1, 2016. Each of the selling stockholders may offer shares of Common Stock under this prospectus from time to time and may elect to sell none, some or all of the shares of Common Stock set
forth next to its name. As a result, we cannot estimate the number of shares of Common Stock each of the selling stockholders will beneficially own after termination of sales under this prospectus. In addition, each of the selling stockholders may
have sold, transferred or otherwise disposed of all or a portion of such holder’s shares of Common Stock since the date on which it provided information for this table. We have not made independent inquiries about this.
Beneficial ownership is determined in accordance with the rules and regulations of the SEC and includes voting or investment power with respect to our Common Stock.
We are relying on written commitments from each of the selling stockholders to notify us of any changes in its beneficial ownership after the date it originally
provided the information below. See “Plan of Distribution” beginning on page 5.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling Security Holder(1)
|
|
# of Shares
held before
Offering
|
|
|
# Shares Being
Offered
|
|
|
# of Shares
held after
Offering(2)
|
|
|
Percentage of
Shares
After Offering(2)
|
|
|
OrbiMed Partners Master Fund Limited (3)
|
|
|
1,380,573
|
|
|
|
1,380,573
|
|
|
|
—
|
|
|
|
—
|
|
|
OrbiMed Partners II, LP (3)
|
|
|
1,161,800
|
|
|
|
1,161,800
|
|
|
|
—
|
|
|
|
—
|
|
|
RA Capital Healthcare Fund, L.P. (4)
|
|
|
1,241,695
|
|
|
|
1,241,695
|
|
|
|
—
|
|
|
|
—
|
|
|
Blackwell Partners LLC – Series A (5)
|
|
|
283,729
|
|
|
|
283,729
|
|
|
|
—
|
|
|
|
—
|
|
|
Perceptive Life Sciences Master Fund, Ltd. (6)
|
|
|
847,458
|
|
|
|
847,458
|
|
|
|
—
|
|
|
|
—
|
|
|
Gaoling Fund, L.P. (7)
|
|
|
623,729
|
|
|
|
623,729
|
|
|
|
—
|
|
|
|
—
|
|
|
YHG Investment, L.P. (7)
|
|
|
54,237
|
|
|
|
54,237
|
|
|
|
—
|
|
|
|
—
|
|
|
RTW Master Fund, Ltd.
|
|
|
662,779
|
|
|
|
662,779
|
|
|
|
—
|
|
|
|
—
|
|
|
RTW Innovation Master Fund, Ltd.
|
|
|
15,187
|
|
|
|
15,187
|
|
|
|
—
|
|
|
|
—
|
|
|
667, L.P.(8)
|
|
|
424,844
|
|
|
|
86,600
|
|
|
|
338,244
|
(9)
|
|
|
*
|
|
|
Baker Brothers Life Sciences, L.P. (8)
|
|
|
4,103,113
|
|
|
|
760,858
|
|
|
|
3,342,255
|
(10)
|
|
|
4.88
|
%
|
|
QVT Fund IV LP (11)
|
|
|
87,108
|
|
|
|
87,108
|
|
|
|
—
|
|
|
|
—
|
|
|
QVT Fund V LP (11)
|
|
|
379,997
|
|
|
|
379,997
|
|
|
|
—
|
|
|
|
—
|
|
|
Quintessence Fund L.P. (11)
|
|
|
41,369
|
|
|
|
41,369
|
|
|
|
—
|
|
|
|
—
|
|
|
(1)
|
If required, information about other selling security holders, except for any future transferees, pledgees, donees or successors of the selling security holders named in the table above, will be set forth in a
prospectus supplement or amendment to the registration statement of which this prospectus is a part. Additionally, post-effective amendments to the registration statement will be filed to disclose any material changes to the plan of distribution
from the description contained in the final prospectus.
|
|
(2)
|
Assumes all shares of Common Stock offered by the selling stockholders hereby are sold and that the selling stockholders buy or sell no additional shares of Common Stock prior to the completion of this offering.
|
|
(3)
|
Samuel D. Isaly, Sven H. Borho, Carl L. Gordon, Jonathan T. Silverstein, W. Carter Neild and Geoffrey C. Hsu hold investment and voting control with respect to the Shares owned by OrbiMed Partners Master Fund Limited
and OrbiMed Partners II, LP.
|
|
(4)
|
Peter Kolchinsky, as the Managing Member of RA Capital Management, LLC, which is the General Partner of RA Capital Healthcare Fund, L.P., has voting and investment power over the Shares owned by RA Capital Healthcare
Fund, L.P.
|
|
(5)
|
Peter Kolchinsky, as Managing Member of RA Capital Management, LLC, which is the Investment Adviser for Blackwell Partners LLC—Series A, has voting and investment power over the Shares owned by Blackwell Partners
LLC – Series A.
|
|
(6)
|
Joseph E. Edelman as the General Partner of Perceptive Advisors which is the investment advisor of Perceptive Life Sciences Master Fund, Ltd. has voting and investment power over the Shares owned by Perceptive Life
Sciences Master Fund, Ltd.
|
|
(7)
|
Hillhouse Capital Management, Ltd. (an Exempted Company incorporated in the Cayman Islands) acts as the sole management company of Gaoling Fund, L.P. and YHG Investments, L.P. (each an Exempted Limited Partnership
registered in the Cayman Islands, the “Funds”). Mr. Lei Zhang may be deemed to have controlling power over Hillhouse Capital Management, Ltd. Mr. Lei Zhang disclaims beneficial ownership of all of the Shares held by the Funds,
except to the extent of his pecuniary interest therein.
|
3
|
(8)
|
Julian C. Baker and Felix J. Baker are the managing partners of the advisor Baker Bros. Advisors LP and hold investment and voting power over the Shares owned by 667, L.P. and Baker Brothers Life Sciences, L.P. Baker
Bros. Advisors LP is the investment advisor of 667, LP and Baker Brothers Life Sciences, LP. Julian C. Baker and Felix J. Baker disclaim beneficial ownership of the Shares held by 667, LP and Baker Brothers Life Sciences LP except to the extent of
their indirect pecuniary interest.
|
|
(9)
|
Includes 304,778 shares issuable upon the conversion of the Company’s Series C Preferred Stock.
|
|
(10)
|
Includes 2,366,212 shares issuable upon the conversion of the Company’s Series C Preferred Stock.
|
|
(11)
|
Management of Quintessence Fund L.P., QVT Fund IV LP and QVT Fund V LP is vested in their general partner, QVT Associates GP LLC, which may be deemed to beneficially own the Shares held by Quintessence Fund L.P., QVT
Fund IV LP and QVT Fund V LP. QVT Financial LP is the investment manager of Quintessence Fund L.P., QVT Fund IV LP and QVT Fund V LP and shares voting and investment control over the Shares held by Quintessence Fund L.P., QVT Fund IV LP and QVT
Fund V LP. QVT Financial GP LLC is the general partner of QVT Financial LP and as such has complete discretion in the management and control of the business affairs of QVT Financial LP. The managing members of QVT Financial GP LLC are Daniel
Gold, Nicholas Brumm, Arthur Chu and Tracy Fu. Each of Daniel Gold, Nicholas Brumm, Arthur Chu and Tracy Fu disclaims beneficial ownership of the Shares owned by Quintessence Fund, L.P., QVT Fund IV LP and QVT Fund V LP. Each of QVT Financial
LP, QVT Associates GP LLC and QVT Financial GP LLC disclaims beneficial ownership of such Shares except to the extent of its pecuniary interest therein.
|
4
PLAN OF DISTRIBUTION
The selling stockholders may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of Common Stock or interests in shares of Common
Stock on any stock exchange, market or trading facility on which the Common Stock is traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing
market price, at varying prices determined at the time of sale, or at negotiated prices.
The selling stockholders may use any one or more of the following methods
when disposing of shares or interests therein:
|
|
n
|
|
ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
|
|
|
n
|
|
block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
|
|
|
n
|
|
purchases by a broker-dealer as principal and resale by the broker-dealer for its own account;
|
|
|
n
|
|
an exchange distribution in accordance with the rules of the applicable exchange;
|
|
|
n
|
|
privately negotiated transactions;
|
|
|
n
|
|
short sales effected after the date the registration statement of which this prospectus is a part is declared effective by the SEC;
|
|
|
n
|
|
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
|
|
|
n
|
|
through agreements between broker-dealers and the selling stockholders to sell a specified number of such shares at a stipulated price per share;
|
|
|
n
|
|
a combination of any such methods of sale; and
|
|
|
n
|
|
any other method permitted by applicable law.
|
The selling stockholders may, from time to time, pledge or grant a
security interest in some or all of the shares of Common Stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of Common Stock, from time to time,
under this prospectus, or under an amendment to this prospectus under Rule 424(b) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as
selling stockholders under this prospectus. The selling stockholders also may transfer the shares of Common Stock in other circumstances, in which case the pledgees, transferees or other successors in interest will be the selling beneficial owners
for purposes of this prospectus.
In connection with the sale of our Common Stock or interests therein, the selling stockholders may enter into hedging transactions
with broker-dealers or other financial institutions, which may in turn engage in short sales of the Common Stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our Common Stock short and deliver
these securities to close out their short positions, or loan or pledge the Common Stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into options or other transactions with broker-dealers or other
financial institutions or the creation of one or more derivative securities which require the delivery to each such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial
institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).
The aggregate proceeds to the selling stockholders
from the sale of the Common Stock offered by them will be the purchase price of the Common Stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with its agents from time to time, to
reject, in whole or in part, any proposed purchase of Common Stock to be made directly or through agents. We will not receive any of the proceeds from this offering.
The selling stockholders also may resell all or a portion of the shares of Common Stock in open market transactions in reliance upon Rule 144 under the Securities Act,
provided that they meet the criteria and conform to the requirements of that rule.
The selling stockholders and any underwriters, broker-dealers or agents that
participate in the sale of the Common Stock or interests therein may be “underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares
may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of
the Securities Act.
5
To the extent required, the shares of our Common Stock to be sold, the names of the selling stockholders, the respective
purchase prices and public offering prices, the names of any agents, dealers or underwriters, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if
appropriate, a post-effective amendment to the registration statement that includes this prospectus.
In order to comply with the securities laws of some states,
if applicable, the Common Stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the Common Stock may not be sold unless it has been registered or qualified for sale or an
exemption from registration or qualification requirements is available and is complied with.
We have advised the selling stockholders that the anti-manipulation
rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable we will make copies of this prospectus (as it may
be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates
in transactions involving the sale of the shares of Common Stock against certain liabilities, including liabilities arising under the Securities Act.
We have
agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.
We have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a part effective until the earlier of
(1) such time as all of the shares of Common Stock covered by this prospectus have been disposed of pursuant to and in accordance with the registration statement or (2) the date on which all of the shares of Common Stock may be sold
without restriction pursuant to Rule 144 of the Securities Act.
EXPERTS
The financial statements of the Company incorporated in this prospectus by reference from the Company’s Annual Report on Form 10-K for the year ended
September 30, 2015 have been audited by Rose, Snyder & Jacobs, LLP as stated in their report incorporated by reference, and given upon the authority of said firm as experts in auditing and accounting.
LEGAL MATTERS
Certain legal
matters, including the validity of the securities offered pursuant to this registration statement, will be passed upon for us by Gibson, Dunn & Crutcher LLP, San Francisco, California.
WHERE YOU CAN FIND MORE INFORMATION
We must comply with the informational requirements of the Exchange Act, and we are required to file reports and proxy statements and other information with the SEC.
You may read and copy these reports, proxy statements and other information at the Public Reference Room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may also obtain copies at the prescribed rates from the Public
Reference Section of the Securities and Exchange Commission at its principal office in Washington, D.C. You may call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC also maintains a website that contains
reports, proxy and information statements and other information regarding issuers like us that file electronically with the SEC. You may access the SEC’s web site at http://www.sec.gov. We maintain a website at www.arrowheadpharma.com. The
information contained in, or that can be accessed through, our website is not incorporated by reference herein and is not part of this prospectus.
Statements
contained in this prospectus as to the contents of any contract or other document are not necessarily complete, and in each instance we refer you to the copy of the contract or document filed as an exhibit to the registration statement, each such
statement being qualified in all respects by such reference.
6
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE
The SEC allows us to incorporate by reference in this prospectus the information that we file with it. Incorporation by reference means that we can disclose important
information to you by referring you to other documents that are legally considered to be part of this prospectus. Later information that we file with the SEC will automatically update and supersede the information in this prospectus, any supplement
and the documents listed below. Our SEC file number is 0-21898. We incorporate by reference the specific documents listed below and any future filings made with the SEC under Section 13(a), 13(c), 14, or 15(d) of the Exchange Act, as amended,
until all of the shares of common stock covered by this prospectus are sold:
|
|
n
|
|
The Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2015, filed on December 14, 2015;
|
|
|
n
|
|
The Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended December 31, 2015, March 31, 2016 and June 30, 2016 , filed on February 9, 2016, May 10, 2016 and
August 9, 2016, respectively;
|
|
|
n
|
|
The Company’s Definitive Proxy Statement on Schedule 14A, filed on January 19, 2016;
|
|
|
n
|
|
The Company’s Current Reports on Form 8-K filed on January 14, 2016, March 10, 2016, April 6, 2016 and August 10, 2016;
|
|
|
n
|
|
The description of the Company’s Common Stock contained in its registration statement on Form 8-A/A (Registration No. 000-21898), filed on April 7, 2016, including any amendments or reports filed for the
purpose of updating such description; and
|
|
|
n
|
|
All documents filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, after the date of the original Registration Statement and prior to effectiveness of the registration statement of
which this prospectus is a part, provided that all documents “furnished” by the Company to the SEC and not “filed” are not deemed incorporated by reference herein.
|
We will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any
document incorporated by reference. Requests should be addressed to Corporate Secretary, 225 South Lake Avenue, Suite 1050, Pasadena, CA 91101 or may be made telephonically at (626) 304-3400.
You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized anyone to provide
you with different information. You should not assume that the information contained in this prospectus or the accompanying prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that any
information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any accompanying prospectus supplement is delivered or securities are sold on a
later date.
7
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution (1).
The following are the estimated expenses of the distribution of the shares registered hereunder on Form S-3:
|
|
|
|
|
|
|
Registration Fee—Securities and Exchange Commission
|
|
$
|
5,207.39
|
|
|
Accountants Fees and Expenses
|
|
$
|
10,000
|
|
|
Legal Fees and Expenses
|
|
$
|
10,000
|
|
|
Miscellaneous
|
|
$
|
10,000
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
35,207.39
|
|
|
|
|
|
|
|
|
(1)
|
The amounts set forth below, except for the SEC Registration Fee, are estimated.
|
Item 15.
Indemnification of Directors and Officers.
The Company’s Certificate of Incorporation provides for the elimination of personal
monetary liability of directors to the fullest extent permissible under Delaware law. Delaware law does not permit the elimination or limitation of director monetary liability for: (i) breaches of the director’s duty of loyalty to the
corporation or its stockholders; (ii) acts or omissions not in good faith or involving intentional misconduct or knowing violations of law; (iii) the payment of unlawful dividends or unlawful stock repurchases or redemptions or
(iv) transactions in which the director received an improper personal benefit.
Section 145 of the Delaware General Corporation
Law permits a Delaware corporation to indemnify, on certain terms and conditions, any person who was or is a party or is threatened to be made a party to any threatened pending or completed action, suit or proceeding, whether civil, criminal,
administrative or investigative, by reason of the fact that he is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action. The
Certificate of Incorporation and Bylaws of the Company require the Company to indemnify the Company’s directors and officers to the fullest extent permitted under Delaware law.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Company pursuant to the foregoing provisions, the Company has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
Item 16. Exhibit Index.
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (1)
|
|
|
|
|
3.2
|
|
Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc. (1)
|
|
|
|
|
4.1
|
|
Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc. (1)
|
|
|
|
|
5.1
|
|
Opinion of Gibson, Dunn & Crutcher LLP **
|
|
|
|
|
23.1
|
|
Consent of Rose, Snyder & Jacobs, the registrant’s independent registered public accounting firm**
|
|
|
|
|
23.2
|
|
Consent of Gibson, Dunn & Crutcher LLP (included in legal opinion filed as Exhibit 5.1)**
|
|
|
|
|
24.1
|
|
Power of Attorney (included on signature page)**
|
|
(1)
|
Filed as an exhibit to the registrant’s Current Report on Form 8-K, filed on April 6, 2016, and incorporated by reference herein.
|
II-1
Item 17. Undertakings.
Item 512(a) of Regulation S-K
. The undersigned registrant hereby undertakes:
|
(1)
|
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
|
|
|
(i)
|
To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
|
|
|
(ii)
|
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a
fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was
registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price
represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and
|
|
|
(iii)
|
To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;
|
Provided, however
, That:
Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the
registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.
|
(2)
|
That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and
the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
|
|
(3)
|
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
|
|
(4)
|
That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:
|
|
|
(A)
|
Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in this registration
statement; and
|
|
|
(B)
|
Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or
(x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is
first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial
bona fide
offering thereof.
Provided, however
, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated
by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the
registration statement or prospectus that was part of this Registration Statement or made in any such document immediately prior to such effective date.
|
|
(5)
|
That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:
|
The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to
the purchaser and will be considered to offer or sell such securities to such purchaser:
|
|
(i)
|
Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;
|
II-2
|
|
(ii)
|
Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;
|
|
|
(iii)
|
The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and
|
|
|
(iv)
|
Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.
|
Item 512(b) of Regulation S-K
. The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities
Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (and, where applicable, each filing of an employee benefit plan’s annual
report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
Item 512(h) of Regulation
S-K
. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has
been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such
liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
Item 512(i) of Regulation S-K
. The undersigned registrant hereby undertakes that:
|
|
(i)
|
For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a
form of prospectus filed by the registrant pursuant to Rule 424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.
|
|
|
(ii)
|
For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
|
II-3
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets
all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Pasadena, state of California, on September 2, 2016.
|
|
|
|
|
ARROWHEAD PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
|
/s/ Christopher Anzalone
|
|
|
|
Christopher Anzalone
|
|
|
|
Chief Executive Officer
|
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the
capacities and on the dates indicated, each of whom also constitutes and appoints Christopher Anzalone and Kenneth A. Myszkowski, and each of them singly, his or her true and lawful attorney-in-fact and agent, for him or her, with full power of
substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement, and to file the same and all exhibits thereto and any other documents
in connection therewith with the Securities and Exchange Commission, granting unto each attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents
and purposes as he or she might or could do in person, hereby ratifying and confirming all that each attorney-in-fact and agent or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Christopher Anzalone
Christopher Anzalone
|
|
Chief Executive Officer and President and Director
(Principal Executive Officer)
|
|
September 2, 2016
|
|
|
|
|
|
/s/ Kenneth A. Myszkowski
Kenneth A. Myszkowski
|
|
Chief Financial Officer
(Principal Financial
Officer and Principal
Accounting Officer)
|
|
September 2, 2016
|
|
|
|
|
|
/s/ Douglass Given
Douglass Given
|
|
Director, Chairman of the Board of Directors
|
|
September 2, 2016
|
|
|
|
|
|
/s/ Mauro Ferrari
Mauro Ferrari
|
|
Director
|
|
September 2, 2016
|
|
|
|
|
|
/s/ Edward W. Frykman
Edward W. Frykman
|
|
Director
|
|
September 2, 2016
|
|
|
|
|
|
/s/ Michael S. Perry
Michael S. Perry
|
|
Director
|
|
September 2, 2016
|
EXHIBIT INDEX
|
|
|
|
|
Exhibit
No.
|
|
Description
|
|
|
|
|
3.1
|
|
Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (1)
|
|
|
|
|
3.2
|
|
Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc. (1)
|
|
|
|
|
4.1
|
|
Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc. (1)
|
|
|
|
|
5.1
|
|
Opinion of Gibson, Dunn & Crutcher LLP **
|
|
|
|
|
23.1
|
|
Consent of Rose, Snyder & Jacobs, the registrant’s independent registered public accounting firm**
|
|
|
|
|
23.2
|
|
Consent of Gibson, Dunn & Crutcher LLP (included in legal opinion filed as Exhibit 5.1)**
|
|
|
|
|
24.1
|
|
Power of Attorney (included on signature page)**
|
|
(1)
|
Filed as an exhibit to the registrant’s Current Report on Form 8-K, filed on April 6, 2016, and incorporated by reference herein.
|
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024
